Home LiteratureArticle Details
PMID: 9525604 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Journal of virology ·Vol. 72 ·No. 4 ·1998-04-00 ·Pages 2846-54

Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Kräusslich HG

Abstract

Retroviruses are produced as immature particles containing structural polyproteins, which are subsequently cleaved by the viral proteinase (PR). Extracellular maturation leads to condensation of the spherical core to a capsid shell formed by the capsid (CA) protein, which encases the genomic RNA complexed with nucleocapsid (NC) proteins. CA and NC are separated by a short spacer peptide (spacer peptide 1 [SP1]) on the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein and released by sequential PR-mediated cleavages. To assess the role of individual cleavages in maturation, we constructed point mutations abolishing cleavage at these sites, either alone or in combination. When all three sites between CA and NC were mutated, immature particles containing stable CA-NC were observed, with no apparent effect on other cleavages. Delayed maturation with irregular morphology of the ribonucleoprotein core was observed when cleavage of SP1 from NC was prevented. Blocking the release of SP1 from CA, on the other hand, yielded normal condensation of the ribonucleoprotein core but prevented capsid condensation. A thin, electron-dense layer near the viral membrane was observed in this case, and mutant capsids were significantly less stable against detergent treatment than wild-type HIV-1. We suggest that HIV maturation is a sequential process controlled by the rate of cleavage at individual sites. Initial rapid cleavage at the C terminus of SP1 releases the RNA-binding NC protein and leads to condensation of the ribonucleoprotein core. Subsequently, CA is separated from the membrane by cleavage between the matrix protein and CA, and late release of SP1 from CA is required for capsid condensation.

MeSH Terms
Amino Acid Sequence Animals Binding Sites COS Cells Capsid/drug effects,genetics,metabolism Cell Line Cell Line, Transformed Cloning, Molecular Detergents/pharmacology Gene Products, gag/genetics,metabolism HIV Protease/metabolism HIV-1/drug effects,metabolism,physiology,ultrastructure Humans Molecular Sequence Data Octoxynol/pharmacology Point Mutation Protein Processing, Post-Translational Proteins/genetics,metabolism Virion/physiology,ultrastructure Virus Assembly
Chemicals
Detergents Gene Products, gag Proteins Octoxynol HIV Protease
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Wiegers K
Heinrich-Pette-Institut, Hamburg, Germany.
Rutter G
Kottler H
Tessmer U
Hohenberg H
Kräusslich H G
References (64)
64 references, click to expand
  1. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells.
    Virology. 1992 Jan;186(1):25-39 PMID: 1727601
  2. In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants: identification of the p10 domain as a morphological determinant in the formation of spherical particles.
    J Virol. 1997 Jun;71(6):4425-35 PMID: 9151833
  3. Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation.
    J Gen Virol. 1992 Dec;73 ( Pt 12):3079-86 PMID: 1469349
  4. Identification of proteolytic processing sites within the Gag and Pol polyproteins of feline immunodeficiency virus.
    J Virol. 1993 Apr;67(4):1869-76 PMID: 8383214
  5. Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation.
    Virology. 1993 Apr;193(2):981-5 PMID: 8460500
  6. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
    Virology. 1993 Jun;194(2):843-50 PMID: 8503189
  7. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
    J Virol. 1993 Jul;67(7):4050-5 PMID: 8510215
  8. Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.
    J Virol. 1993 Jul;67(7):4264-73 PMID: 7685414
  9. Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein.
    J Virol. 1993 Oct;67(10):6246-52 PMID: 8396679
  10. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
    J Virol. 1993 Dec;67(12):7229-37 PMID: 8230445
  11. Specificity and sequence requirements for interactions between various retroviral Gag proteins.
    J Virol. 1994 Aug;68(8):5300-5 PMID: 8035530
  12. Amino acid sequence analysis of the proteolytic cleavage products of the bovine immunodeficiency virus Gag precursor polypeptide.
    J Virol. 1994 Nov;68(11):7620-7 PMID: 7933153
  13. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.
    J Virol. 1994 Dec;68(12):8017-27 PMID: 7966591
  14. On the size of the active site in proteases. I. Papain.
    Biochem Biophys Res Commun. 1967 Apr 20;27(2):157-62 PMID: 6035483
  15. A low-viscosity epoxy resin embedding medium for electron microscopy.
    J Ultrastruct Res. 1969 Jan;26(1):31-43 PMID: 4887011
  16. Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.
    Virology. 1983 Aug;129(1):51-64 PMID: 6412453
  17. Rapid and efficient site-specific mutagenesis without phenotypic selection.
    Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92 PMID: 3881765
  18. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
    Science. 1985 Aug 9;229(4713):563-6 PMID: 2992081
  19. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
    J Virol. 1986 Aug;59(2):284-91 PMID: 3016298
  20. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
    Virology. 1987 Jan;156(1):171-6 PMID: 3643678
  21. Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins.
    J Virol. 1987 Apr;61(4):1116-24 PMID: 3029406
  22. High-efficiency transformation of mammalian cells by plasmid DNA.
    Mol Cell Biol. 1987 Aug;7(8):2745-52 PMID: 3670292
  23. Standardized and simplified nomenclature for proteins common to all retroviruses.
    J Virol. 1988 May;62(5):1808-9 PMID: 3357211
  24. Active human immunodeficiency virus protease is required for viral infectivity.
    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 PMID: 3290901
  25. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne).
    J Virol. 1988 Aug;62(8):2587-95 PMID: 3292789
  26. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.
    J Virol. 1988 Nov;62(11):3993-4002 PMID: 3262776
  27. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.
    J Virol. 1988 Nov;62(11):4393-7 PMID: 3050149
  28. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.
    J Virol. 1989 Jun;63(6):2550-6 PMID: 2657099
  29. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1989 Aug;86(15):5781-5 PMID: 2788277
  30. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.
    Cell. 1989 Oct 6;59(1):103-12 PMID: 2676191
  31. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.
    AIDS Res Hum Retroviruses. 1989 Dec;5(6):577-91 PMID: 2692658
  32. Sensitive, soluble chromogenic substrates for HIV-1 proteinase.
    J Biol Chem. 1990 May 15;265(14):7733-6 PMID: 2186027
  33. Properties of avian retrovirus particles defective in viral protease.
    J Virol. 1990 Oct;64(10):5076-92 PMID: 1697912
  34. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.
    J Virol. 1991 Feb;65(2):922-30 PMID: 1987379
  35. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3195-9 PMID: 2014240
  36. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid.
    J Biol Chem. 1991 Aug 5;266(22):14539-47 PMID: 1860860
  37. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base.
    J Biol Chem. 1991 Aug 5;266(22):14554-61 PMID: 1860861
  38. Assembly and morphology of HIV: potential effect of structure on viral function.
    AIDS. 1991 Jun;5(6):617-37 PMID: 1652977
  39. Form, function, and use of retroviral gag proteins.
    AIDS. 1991 Jun;5(6):639-54 PMID: 1883539
  40. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor.
    Arch Virol. 1991;120(1-2):71-81 PMID: 1929879
  41. Functional domains of the capsid protein of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8180-7 PMID: 7966609
  42. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity.
    J Virol. 1995 Feb;69(2):642-50 PMID: 7815527
  43. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases.
    Eur J Biochem. 1995 Feb 15;228(1):191-8 PMID: 7883003
  44. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
    J Virol. 1995 May;69(5):2751-8 PMID: 7535864
  45. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity.
    J Virol. 1995 Jun;69(6):3407-19 PMID: 7745687
  46. Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses.
    J Virol. 1995 Oct;69(10):6430-8 PMID: 7666544
  47. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.
    J Virol. 1995 Oct;69(10):6487-97 PMID: 7666550
  48. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.
    J Virol. 1995 Nov;69(11):7180-6 PMID: 7474139
  49. Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly.
    J Gen Virol. 1996 Apr;77 ( Pt 4):743-51 PMID: 8627263
  50. Structure of the amino-terminal core domain of the HIV-1 capsid protein.
    Science. 1996 Jul 12;273(5272):231-5 PMID: 8662505
  51. Crystal structure of dimeric HIV-1 capsid protein.
    Nat Struct Biol. 1996 Sep;3(9):763-70 PMID: 8784350
  52. Comparative morphology and structural classification of retroviruses.
    Curr Top Microbiol Immunol. 1996;214:1-24 PMID: 8791723
  53. Intracellular transport of retroviral capsid components.
    Curr Top Microbiol Immunol. 1996;214:25-63 PMID: 8791724
  54. Dynamic interactions of the Gag polyprotein.
    Curr Top Microbiol Immunol. 1996;214:65-94 PMID: 8791725
  55. Proteolytic processing and particle maturation.
    Curr Top Microbiol Immunol. 1996;214:95-131 PMID: 8791726
  56. RNA packaging.
    Curr Top Microbiol Immunol. 1996;214:177-218 PMID: 8791728
  57. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.
    Science. 1997 Oct 31;278(5339):849-53 PMID: 9346481
  58. Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle.
    Curr Biol. 1997 Oct 1;7(10):729-38 PMID: 9368755
  59. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus.
    Eur J Biochem. 1997 Oct 15;249(2):592-600 PMID: 9370371
  60. Genetic determinants of Rous sarcoma virus particle size.
    J Virol. 1998 Jan;72(1):564-77 PMID: 9420260
  61. N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles.
    J Virol. 1998 Jun;72(6):4798-810 PMID: 9573245
  62. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.
    Cell. 1996 Dec 27;87(7):1285-94 PMID: 8980234
  63. The morphology of the immature HIV-1 virion.
    Virology. 1997 Feb 3;228(1):112-4 PMID: 9024816
  64. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.
    J Virol. 1992 Apr;66(4):1856-65 PMID: 1548743
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1998-04-00
Pages
2846-54
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC109729
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]